An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Pharmaron’s Liverpool UK Gene Therapy CDMO Commences Major Site Expansion Following UK Government Grant to Support £151m Investment
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Pharmaron Beijing Co. has announced a substantial expansion of its Gene Therapy CDMO facility in Liverpool, UK, after securing a grant from the UK Government’s Life Sciences Innovation Manufacturing Fund. This £151M project will quadruple its gene therapy development capacity, adding over 8,000 sqM focused on viral vector, DNA, and RNA production. The expansion, which began in January 2023 and is expected to complete in 2024, aims to support 29 ongoing gene therapy and vaccine projects and bolster Pharmaron's scientific team. The facility was acquired from AbbVie in 2021, and growth is anticipated to continue through the existing operations.
Positive
Awarded a £151M grant from the UK Government to expand facilities.
Expansion will increase development capacity for gene therapies four-fold.
The facility will support 29 ongoing projects, indicating strong business demand.
Negative
None.
Building capacity in Gene Therapy
BEIJING--(BUSINESS WIRE)--
Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSMIF) to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM.
This major expansion project will provide a four-fold increase in gene therapy process development and analytical capacity accommodating viral vector, DNA and RNA drug substance, plus drug product formulation. The expansion includes 3,500 sqM for future commercial scale GMP capacity.
The resulting facility will greatly enhance the scale and scope of Pharmaron’s services to vaccine, cell and gene therapy customers and allows Pharmaron to continue expanding its scientific team at Liverpool. The total investment in capital and people for this expansion is estimated to be in the region of £151M.
Pharmaron acquired the established Liverpool CGT facility from AbbVie in 2021 and has rapidly added customers with 29 gene therapy and vaccine projects running through 2022. The expansion will allow this pace of growth to continue beyond the capacity of the existing state-of-the-art development and GMP facility, which will remain fully operational during, and after, the expansion project.
Construction activities commenced in January 2023 and facility handover is expected in 2024.
Dr. Boliang Lou, Chairman and Chief Executive Officer of Pharmaron, commented, “I am delighted that we have been awarded this funding from the UK Government. Securing this grant demonstrates UK Government’s support and trust in Pharmaron to continuously expand our state-of-the-art infrastructure and top-notch scientific team at Liverpool to serve the gene therapy and vaccine development community in UK and abroad. We look forward to our new facilities coming online to support our partners that are delivering innovative, life changing medicines for patients in 2025.”
About Pharmaron
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and cell & gene therapy products. With over 19,000 employees, and operations in China, UK and US, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners globally.
Pharmaron’s GT CDMO operates out of state-of-the-art facilities in Liverpool, UK that were previously Allergan’s global centre of excellence for biologic drug substance development and divested by AbbVie in May 2021 following the acquisition of Allergan. Pharmaron has since launched a CDMO business from the site and continued to invest in world class innovation in viral vector and gene therapy analytical and process technology to support partners around the world. www.pharmaron.com
Collaboration with Vaccitech plc (NASDAQ: VACC) to support its novel T cell immunotherapeutics and vaccines development and manufacturing;
Strategic partnership for the Development and Clinical Manufacture of a Gene Therapy for the treatment of Geographic Atrophy with Complement Therapeutics Ltd (CTx).
What expansion has Pharmaron announced in Liverpool?
Pharmaron is expanding its Gene Therapy CDMO facility in Liverpool, UK, through a £151M grant from the UK Government, which will quadruple its development capacity.
How much will Pharmaron's expansion facility cost?
The expansion project is estimated to cost £151M.
What is the expected completion date for the Pharmaron facility expansion?
The facility expansion is expected to be completed in 2024.
Which projects will benefit from Pharmaron's facility expansion?
The expansion will support 29 ongoing gene therapy and vaccine projects.
What significant grant did Pharmaron receive for its expansion?
Pharmaron received a grant from the UK Government's Life Sciences Innovation Manufacturing Fund to facilitate its facility expansion.
